Millennium Management’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-477,189
| Closed | -$4.76M | – | 6244 |
|
|
2025
Q2 | $4.76M | Buy |
477,189
+128,830
| +37% | +$1.04M | ﹤0.01% | 3051 |
|
|
2025
Q1 | $2.08M | Sell |
348,359
-62,713
| -15% | -$460K | ﹤0.01% | 3750 |
|
|
2024
Q4 | $3.16M | Buy |
411,072
+373,999
| +1,009% | +$3.21M | ﹤0.01% | 3255 |
|
|
2024
Q3 | $379K | Sell |
37,073
-204,232
| -85% | -$3.12M | ﹤0.01% | 5043 |
|
|
2024
Q2 | $3.58M | Sell |
241,305
-641,676
| -73% | -$9.19M | ﹤0.01% | 3034 |
|
|
2024
Q1 | $12M | Sell |
882,981
-84,421
| -9% | -$920K | 0.01% | 2015 |
|
|
2023
Q4 | $10.6M | Sell |
967,402
-65,444
| -6% | -$649K | ﹤0.01% | 2123 |
|
|
2023
Q3 | $11.3M | Buy |
1,032,846
+206,744
| +25% | +$2.64M | 0.01% | 1934 |
|
|
2023
Q2 | $10.9M | Buy |
826,102
+297,830
| +56% | +$4.25M | 0.01% | 1934 |
|
|
2023
Q1 | $7.19M | Sell |
528,272
-346,208
| -40% | -$6.2M | ﹤0.01% | 2270 |
|
|
2022
Q4 | $17.1M | Buy |
874,480
+136,124
| +18% | +$2.66M | 0.01% | 1587 |
|
|
2022
Q3 | $14.1M | Buy |
738,356
+413,659
| +127% | +$9.53M | 0.01% | 1733 |
|
|
2022
Q2 | $6.69M | Buy |
324,697
+49,837
| +18% | +$1.18M | ﹤0.01% | 2492 |
|
|
2022
Q1 | $8.85M | Buy |
274,860
+47,424
| +21% | +$1.72M | ﹤0.01% | 2285 |
|
|
2021
Q4 | $10.6M | Buy |
+227,436
| New | +$7.57M | 0.01% | 2085 |
|
|
2021
Q3 | – | Sell |
-10,389
| Closed | -$266K | – | 7013 |
|
|
2021
Q2 | $266K | Sell |
10,389
-4,204
| -29% | -$100K | ﹤0.01% | 5824 |
|
|
2021
Q1 | $499K | Sell |
14,593
-1,216
| -8% | -$43.9K | ﹤0.01% | 4828 |
|
|
2020
Q4 | $535K | Buy |
+15,809
| New | +$419K | ﹤0.01% | 4138 |
|
Other funds holding ITOS
Millennium Management's ITOS Position: Q3 2025 in Review
Millennium Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 477,189 shares — an estimated $4.76M sold.
Millennium Management first reported a position in ITOS in Q4 2020 and held it in 18 quarters. The position peaked at $17.1M in Q4 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Millennium Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Millennium Management sold 477,189 iTeos Therapeutics shares in Q3 2025, an estimated $4.76M.
- Millennium Management first reported a position in iTeos Therapeutics in Q4 2020 and held it in 18 quarters.
- Millennium Management's iTeos Therapeutics position peaked at $17.1M in Q4 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.